Roche dominates Polivy market in 2024, report finds

The Business Research Company says F. Hoffmann‑La Roche AG held 100% of global Polivy sales in 2024, underscoring a highly concentrated market for the lymphoma therapy. The report points to reimbursement expansion, antibody-drug conjugate innovation and biomarker-driven treatment strategies as key drivers of future competition.

Why it matters: - Polivy is part of a narrow oncology market centered on antibody-drug conjugates and targeted lymphoma treatment. - Roche’s complete share of global sales in 2024 shows how concentrated the market remains. - Wider reimbursement and clinical use could shape access for patients with large B-cell lymphoma.

What happened: - The Business Research Company published its Polivy Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035. - The report says F. Hoffmann‑La Roche AG led global Polivy sales in 2024 with a 100% market share. - Roche Canada announced public reimbursement of Polivy (polatuzumab vedotin) in Quebec in March 2026 for first-line treatment of adults with large B-cell lymphoma.

The details: - The report describes the Polivy market as highly concentrated, with the top player accounting for 100% of market revenue in 2024. - It cites clinical development complexity, strict regulatory approval requirements and specialized biologics manufacturing as barriers to competition. - Roche’s oncology portfolio is positioned around targeted hematology treatments, lymphoma management, precision oncology and biologic innovation. - Major raw material suppliers listed in the report include Lonza Group AG, Catalent Inc., AGC Biologics, Samsung Biologics Co. Ltd., FUJIFILM Diosynth Biotechnologies, Wacker Chemie AG, Merck KGaA, Thermo Fisher Scientific Inc., Cytiva, Sartorius AG, Evonik Industries AG, Ajinomoto Bio-Pharma Services, CordenPharma International, Sterling Pharma Solutions, Bio-Rad Laboratories Inc., WuXi Biologics, Repligen Corporation, Cambrex Corporation, Asahi Kasei Corporation and Charles River Laboratories International Inc. - Major wholesalers and distributors listed include Cencora Inc., Cardinal Health Inc., Morris & Dickson Co. LLC, FFF Enterprises Inc., Anda Inc., CuraScript SD, Oncology Supply, Besse Medical, ASD Healthcare, McKesson Specialty Health, Biologics by McKesson, McKesson Plasma and Biologics, Cardinal Health Specialty Pharmaceutical Distribution, BioCareSD LLC, CVS Specialty Inc., Accredo Health Group Inc., Walgreens Specialty Pharmacy, Optum Specialty Pharmacy and CarelonRx Specialty. - Major end users named in the report include MD Anderson Cancer Center, Dana-Farber Cancer Institute, Stanford Health Care, Mass General Cancer Center, City of Hope Comprehensive Cancer Center, Northwestern Medicine Cancer Center, Mount Sinai Health System, Vanderbilt-Ingram Cancer Center, Roswell Park Comprehensive Cancer Center, Huntsman Cancer Institute, Fred Hutch Cancer Center, Yale Cancer Center, UC San Diego Health Cancer Services, The Royal Marsden NHS Foundation Trust, Princess Margaret Cancer Centre, National University Cancer Institute Singapore and Peter MacCallum Cancer Centre. - The report also highlights market-report features including market attractiveness scoring, TAM analysis, company scoring matrices, Excel dashboards, market hotspot infographics and updated graphics and tables.

Between the lines: - Roche’s apparent monopoly suggests Polivy competition is driven more by regulatory milestones and broader access than by share capture. - The report frames antibody-drug conjugate innovation as the main route to better precision, especially in diffuse large B-cell lymphoma. - Combination regimens, biomarker-driven approaches and clinical trial investment appear to be the strategic levers for any future competitive shift.

What's next: - The report expects precision oncology demand, novel lymphoma therapies and biomarker-driven treatment approaches to support continued investment in the category. - It says pipeline advancement, clinical expansion and oncology research spending should reinforce the position of leading companies. - Future market movement will likely depend on additional approvals, reimbursement decisions and broader clinical adoption across hematologic cancer care.

The bottom line: - Polivy’s market is currently defined by one company, one therapy and one narrow competitive lane — but access decisions and treatment innovation could reshape that picture over time. - More information